Company Nabriva Therapeutics PLC - ADR Nasdaq
Equities
US62957M1045
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Anti-infective Agents
100.0
%
| 29 | 100.0 % | 37 | 100.0 % | +27.82% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Austria, Ireland, and United States
100.0
%
| 29 | 100.0 % | 37 | 100.0 % | +27.82% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 06/07/23 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 29/06/23 |
Steven Gelone
BRD | Director/Board Member | 56 | 22/06/17 |
Director/Board Member | 69 | 23/07/18 | |
Kim Anderson
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 22/06/17 |
Director/Board Member | 69 | 23/07/18 | |
Stephen Webster
BRD | Director/Board Member | 63 | 31/07/16 |
Charles Rowland
BRD | Director/Board Member | 65 | 31/12/14 |
Steven Gelone
BRD | Director/Board Member | 56 | 22/06/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,230,837 | 3,200,138 ( 99.05 %) | 0 | 99.05 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |